1BT Stock Overview
Operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Enlivex Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$3.92 |
| 52 Week Low | US$0.79 |
| Beta | 1.1 |
| 11 Month Change | -40.15% |
| 3 Month Change | -27.52% |
| 1 Year Change | -52.12% |
| 33 Year Change | -87.26% |
| 5 Year Change | -89.74% |
| Change since IPO | -92.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1BT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -21.0% | -0.7% | -0.02% |
| 1Y | -52.1% | -17.2% | 8.2% |
Return vs Industry: 1BT underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 1BT underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 1BT volatility | |
|---|---|
| 1BT Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1BT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1BT's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Oren Hershkovitz | www.enlivex.com |
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.
Enlivex Therapeutics Ltd. Fundamentals Summary
| 1BT fundamental statistics | |
|---|---|
| Market cap | €17.29m |
| Earnings (TTM) | -€21.41m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs 1BT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$22.29m |
| Earnings | -US$22.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1BT perform over the long term?
See historical performance and comparison